Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

115.39 -1.09 (-0.94%)
Streaming Delayed Price Updated: 2:34 PM EDT, Oct 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,915,370
Open 116.24
Bid (Size) 115.37 (1)
Ask (Size) 115.39 (1)
Prev. Close 116.48
Today's Range 115.07 - 116.33
52wk Range 86.96 - 148.15
Shares Outstanding N/A
Dividend Yield 1.53%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Popular Weight Loss Drugs Like Ozempic Show Gap Between Clinical Trial Promises And Real-World Use, Study Reveals
Real-world studies on GLP-1s like Ozempic show lower weight loss than clinical trials, with high discontinuation rates due to adverse effects, costs, and unmet expectations, raising concerns about... 
Via Benzinga
Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected
Guidance for the second cycle of Medicare drug price negotiations has expectations high for significant savings by 2026. 
Via Benzinga

Performance

YTD
+13.01%
+13.01%
1 Month
-15.32%
-15.32%
3 Month
-16.91%
-16.91%
6 Month
-9.13%
-9.13%
1 Year
+31.45%
+31.45%

More News

Read More
Hims & Hers Health Stock Is Tumbling Thursday: Here's Why
Via Benzinga
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
This Is What Whales Are Betting On Novo Nordisk
Via Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $4,700 Today
Via Benzinga
Tandem Diabetes Insulin Pump Demand to Surge Despite Popular Demand Of Weight Loss Drugs, Bullish Analyst Says
Via Benzinga
Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges
Via Benzinga
Eli Lilly Invests $4.5B In New Medicine Foundry for Advanced Drug Manufacturing To Push US Pharma Boundaries
Via Benzinga
3 Momentum Trades Too Good Pass Up
Via MarketBeat
Topics ETFs
Eli Lilly Nears First Trillion Pharma Title, But Investors Caution Amid Sky-High Valuation
Via Benzinga
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
Via Benzinga
Topics Economy
Exposures Interest Rates
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
Via Investor Brand Network
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
Via FinancialNewsMedia
Roche Fast-Tracks Obesity Drug Development, Eyes Over $3B Sales Potential
Via Benzinga
Investors should take note of NYSE:NVO, a growth stock that remains attractively priced.
Via Chartmill
'Stop Ripping Us Off' – Incredibly, Elon Musk And Bernie Sanders Seem To Agree On This One Thing – 'I Really Am With Bernie On This One'
Via Benzinga
Success in This New Battleground Could Make Eli Lilly and Novo Nordisk Stock Absolutely Fly for Years
Via The Motley Fool
Benzinga Bulls And Bears: Apple, Tesla, Novo Nordisk, Bitcoin — And Shiba Inu's Major Stablecoin Tease
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Latest Inflation Data Cements Fed's Interest Rate Call, S&P 500 Hits All-Time High, Biden Adviser Backs China EV Ban At Detroit Economic Club: This Week In The Markets
Via Benzinga
Topics Artificial Intelligence Economy Stocks
Exposures Artificial Intelligence Interest Rates US Equities
Novo Nordisk Slips On Analyst Warning Of Weaker Wegovy Sales
Via Investor's Business Daily
Cassava Sciences, enVVeno Medical And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy?
Via The Motley Fool
Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development
Via Benzinga
Forget Novo Nordisk, Buy This Magnificent Dividend Stock Instead
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.